Data from a small phase 1 study published in Nature indicate that patients with pancreatic ductal adenocarcinoma (PDAC) who respond to treatment with the neoantigen vaccine autogene cevumeran (AC) (BioNTech and Genentech) had statistically significant improvements in median-term recurrence-free survival (RFS) compared with study participants who did not respond to vaccination (2023 May 10. doi:10.1038/s41586-023-06063-y).
“This study shows that personalized RNA vaccines can be administered